Subject characteristics
| T1D subjects | |||
|---|---|---|---|
| Before islet transplantation | After islet transplantation | Nondiabetic control subjects | |
| Male/female sex (n) | 5/7 | 5/7 | 4/4 |
| Age (years) | 45 ± 3 | 47 ± 3** | 44 ± 3 |
| Weight (kg) | 71 ± 3 | 65 ± 3** | 77 ± 5 |
| BMI (kg/m2) | 25 ± 1 | 23 ± 1** | 25 ± 1 |
| HbA1c (%)a | 7.1 ± 0.2 | 5.6 ± 0.1** | 5.5 ± 0.1** |
| T1D duration (years) | 29 ± 4 | 31 ± 4** | — |
| Insulin use (units ⋅ kg−1 ⋅ day−1) | 0.48 ± 0.05 | 0.06 ± 0.05** | — |
| IE/kg transplanted | — | 9,648 ± 666 | — |
| Tacrolimus (μg/L) | — | 4.3 ± 0.4 | — |
| Sirolimus (μg/L)b | — | 8.4 ± 0.5 | — |
| Clarke scorec | 6.3 ± 0.2 | 0.4 ± 0.3** | — |
| HYPO scored | 2,564 ± 715 | ND | — |
| Lability indexe | 719 ± 67 | 93 ± 56** | — |
Data are mean ± SE. IE/kg, islet equivalent (whereby an islet equivalent approximates a standard islet diameter of 150 μm) transplanted per kilogram of recipient body weight; ND, not done.
aTo convert to mmol/mol, multiply by 10.93 and subtract 23.50.
bOne subject was converted from sirolimus to mycophenolate mofetil as a result of the development of interstitial pneumonia 4 weeks after transplant that subsequently resolved (9).
cClarke score of hypoglycemia unawareness (7 = most, 0 = none) (12).
dHYPO score of hypoglycemia severity developed by Ryan et al. (13).
eLability index measure of glycemic lability developed by Ryan et al. (13).
**P < 0.01 for comparison with T1D subjects before transplantation.